Captor Capital Corp Share Price Canadian Securities Exchange
Equities
CA14075H1038
Pharmaceuticals
Sales 2022 | 32.74M 23.94M 1.89B | Sales 2023 | 41.84M 30.6M 2.42B | Capitalization | 20.84M 15.24M 1.2B |
---|---|---|---|---|---|
Net income 2022 | -14M -10.24M -808M | Net income 2023 | -13M -9.51M -751M | EV / Sales 2022 | 0.61 x |
Net cash position 2022 | 13.83M 10.12M 799M | Net cash position 2023 | 10.67M 7.8M 616M | EV / Sales 2023 | 0.24 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-1.6
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.27% |
Managers | Title | Age | Since |
---|---|---|---|
John Zorbas
CEO | Chief Executive Officer | 53 | 31/12/17 |
Jing Peng
DFI | Director of Finance/CFO | 47 | 28/02/14 |
Gavin Davidson
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Klein
BRD | Director/Board Member | 50 | 20/11/19 |
Kyle Appleby
BRD | Director/Board Member | 48 | 30/06/14 |
John Zorbas
CEO | Chief Executive Officer | 53 | 31/12/17 |
1st Jan change | Capi. | |
---|---|---|
+29.76% | 5.69B | |
-32.34% | 3.53B | |
-2.23% | 3.06B | |
-25.26% | 2.62B | |
-10.88% | 2.29B | |
+40.09% | 1.86B | |
+40.90% | 1.43B | |
-15.16% | 1.41B | |
+42.86% | 1.4B |